- Home
- SSNC vs GMAB Comparison
SSNC vs GMAB Comparison
Compare SSNC & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSNC
- GMAB
- Stock Information
- Founded
- SSNC 1986
- GMAB 1999
- Country
- SSNC United States
- GMAB Denmark
- Employees
- SSNC N/A
- GMAB N/A
- Industry
- SSNC EDP Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SSNC Technology
- GMAB Health Care
- Exchange
- SSNC Nasdaq
- GMAB Nasdaq
- Market Cap
- SSNC 16.7B
- GMAB 15.0B
- IPO Year
- SSNC 1996
- GMAB N/A
- Fundamental
- Price
- SSNC $76.38
- GMAB $22.96
- Analyst Decision
- SSNC Buy
- GMAB Buy
- Analyst Count
- SSNC 8
- GMAB 8
- Target Price
- SSNC $73.75
- GMAB $43.00
- AVG Volume (30 Days)
- SSNC 1.3M
- GMAB 1.0M
- Earning Date
- SSNC 10-24-2024
- GMAB 11-06-2024
- Dividend Yield
- SSNC 1.31%
- GMAB N/A
- EPS Growth
- SSNC 14.23
- GMAB 19.99
- EPS
- SSNC 2.77
- GMAB 12.13
- Revenue
- SSNC $5,664,000,000.00
- GMAB $2,732,097,558.00
- Revenue This Year
- SSNC $7.58
- GMAB $30.45
- Revenue Next Year
- SSNC $4.98
- GMAB $16.19
- P/E Ratio
- SSNC $27.54
- GMAB $18.06
- Revenue Growth
- SSNC 5.19
- GMAB 17.19
- 52 Week Low
- SSNC $46.61
- GMAB $22.52
- 52 Week High
- SSNC $76.95
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- SSNC 63.45
- GMAB 31.19
- Support Level
- SSNC $73.69
- GMAB $22.52
- Resistance Level
- SSNC $74.73
- GMAB $23.75
- Average True Range (ATR)
- SSNC 0.99
- GMAB 0.28
- MACD
- SSNC 0.20
- GMAB 0.01
- Stochastic Oscillator
- SSNC 86.87
- GMAB 23.40
About SSNC SS&C Technologies Holdings Inc.
SS&C Technologies provides software products and software-enabled services to a variety of customers primarily in financial services but also healthcare firms. SS&C GlobeOp provides fund administration services to alternative and traditional asset managers. In addition, SS&C provides portfolio accounting, portfolio management, trading, banking/lending, and other software to asset managers, banks, and financial advisors. SS&C's purchase of Intralinks makes it a leading player in Virtual Data Room solutions. With its 2018 purchase of DST Systems, SS&C gained a foothold in the healthcare industry with pharmacy health management solutions and medical claim administration services. In 2022, SS&C completed the acquisition of Blue Prism.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.